Paushak Ltd is India’s largest manufacturer of specialty chemicals built around phosgene, a reactive gas that becomes the molecular backbone for intermediates used in pharmaceuticals, agrochemicals and performance materials. Incorporated in 1972 as part of the Alembic Group, the company has spent the last five decades quietly moving from batch processing to automated, world-scale continuous manufacturing at its single plant in Panelav, Gujarat. The recurring approach is to pick a handful of phosgene derivatives, build indigenous technology to make them at a scale that reduces India’s import dependence, and then become the domestic market leader in those products - a formula it has repeated across chloroformates, isocyanates and carbamoyl chlorides.
Business segments
A single-engine specialty chemicals company - one plant, one chemistry, three product families - serving pharmaceutical, agrochemical and performance-chemical customers across India and export markets.
1. Phosgene derivatives: the partner-of-choice supplier for India’s pharma and agrochemical industries
Paushak makes intermediates that other manufacturers cannot easily replicate, because phosgene is too hazardous for most customers to handle in-house - so they buy from a specialist who has already invested in the safety systems and scale.
- Three product families, one chemistry - the company’s output is organised around chloroformates, isocyanates and carbamoyl chlorides, all derived from phosgene gas that Paushak generates on-site using carbon dioxide as a major raw material.
- The safety moat is real - phosgene is toxic and tightly regulated under the Chemical Weapons Convention, so the company operates a Distributed Control System that can automatically shut down affected plants, emergency scrubbers with UPS backup, and water-curtain systems for fugitive emissions - barriers that make it uneconomical for most downstream players to bring production in-house.
- Sold where the molecule matters - customers are pharmaceutical, agrochemical and performance-chemical companies that use these intermediates as building blocks; no single customer accounted for 10% or more of revenue in FY26, so the business is not tied to any one buyer’s cycle.
- Domestic first, with an export tail - products reach 14 Indian states and 11 countries, with exports contributing roughly 18% of turnover in FY26, up from about 11% the year before.
- Scale that replaced imports - after tripling phosgene capacity to 14,400 tonnes per year and commissioning a multi-purpose derivatives plant in FY22, Paushak became the first large-scale commercial supplier of these products in India, directly reducing the import bill for domestic pharma and agrochemical intermediates.
2. Custom synthesis and job work: the R&D-led extension
When a global innovator needs a phosgene-based intermediate made to its own specification, Paushak runs it as a custom job - same plant, same chemistry, higher stickiness.
- Bespoke batches for innovators - the company earns revenue from custom synthesis and job work, where it manufactures intermediates to a customer’s proprietary specification using its phosgene platform, with revenue recognised on agreed terms rather than standard product pricing.
- Audited by the buyers themselves - the automated plants commissioned in the expansion have been visited and audited by global customers and innovators from the pharmaceutical and agrochemical segments, which acts as both a quality signal and a switching-cost barrier.
- A new R&D complex is being added - the company is building a dedicated R&D facility to provide innovative solutions to partners, signalling that custom synthesis is expected to grow beyond the current footprint.
3. Wind power: a captive energy sideline
Paushak owns wind-power assets that feed clean electricity into the state grid - a small, recurring other-income stream that also helps manage its Scope 2 emissions profile.
- Power sold to the electricity board - the company recognises income from the sale of wind-generated power to the State Electricity Board on an accrual basis once units generated and supplied are confirmed.
- Clean-energy hedge - the wind investment is described as a clean energy source, and it contributes to the company’s stated ESG targets, which include reducing Scope 2 emissions by 35% over five years.
Group structure and partners
Paushak is a standalone listed entity within the Alembic Group, with no subsidiaries and a web of cross-holdings that tie it to the group’s industrial and pharmaceutical heritage.
- Held by the group, not a holding-company structure - the immediate holding company is Nirayu Private Limited, which held just 0.58% of Paushak’s shares as of the reporting date, while the company itself holds quoted investments in Alembic Limited and Alembic Pharmaceuticals Limited.
- No subsidiaries, no international offices - the entire business operates from one manufacturing plant and two offices, all in India, making it a pure domestic manufacturer with an export order book rather than a multinational.
- CSR runs through group foundations - community spending flows through entities such as the Alembic CSR Foundation, Bhailal Amin General Hospital and Rural Development Society, focusing on education, healthcare and rural development around the plant’s catchment area.